Researchers found patients with stage III non-small cell lung cancer who received FDG-PET/CT-guided concurrent chemoradiotherapy with training and quality control support benefited from increased treatment accuracy. The findings were published in the European Journal of Nuclear Medicine and Molecular Imaging.
Study evaluates PET/CT-guided chemoradiotherapy in NSCLC
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.